In situ genetic engineering of tumors for long-lasting and systemic immunotherapy.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: 2020-02-07

DOI: 10.1073/pnas.1916039117

Affiliations: 9

Authors: 6

Go to article
Institutions Share
Department of Biomedical Engineering (BME), JHU, United States of America (USA) 0.30
Translational Tissue Engineering Center (TTEC), JHU, United States of America (USA) 0.30
Institute for NanoBioTechnology (INBT), JHU, United States of America (USA) 0.30
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA) 0.02
Department of Materials Science and Engineering, JHU, United States of America (USA) 0.02
Department of Chemical and Biomolecular Engineering, JHU, United States of America (USA) 0.02
Department of Neurology and Neurosurgery, JHU, United States of America (USA) 0.02
Wilmer Eye Institute at Johns Hopkins, United States of America (USA) 0.02
Bloomberg-Kimmel Institute for Cancer Immunotherapy, JHU, United States of America (USA) 0.02

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER